Skip to main content
. 2011 Nov 9;343:d6884. doi: 10.1136/bmj.d6884

Table 3.

 Incremental costs, DALYs, and cost effectiveness ratios for antiretroviral monitoring study, Tororo and Busia Districts, Uganda, 2003-7

Cost ($) Incremental cost ($) DALYs incurred Incremental DALYs averted ICER: $ per DALY averted
Clinical 606 260 466.4
Clinical/CD4 626 718 20 458 349.1 117.3 174
Clinical/CD4/viral load 769 177 142 458 321.6 27.5 5181